MedTrace Logo

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT00840684 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2011-05-13

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as laromustine, daunorubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of laromustine when given together with daunorubicin and cytarabine in treating patients with acute myeloid leukemia.

Conditions

Interventions

DRUG

amsacrine

DRUG

busulfan

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

laromustine

DRUG

melphalan

DRUG

mitoxantrone hydrochloride

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

autologous hematopoietic stem cell transplantation

Sponsors & Collaborators

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • Norbert Vey, MD · Institut Paoli-Calmettes

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00840684 on ClinicalTrials.gov